📄 medicine

Risks associated with the combination of Darolutamide and Docetaxel in interstitial lung disease : a pharmacovigilance study based on the FAERS database

This pharmacovigilance study utilizing the FAERS database and multi-method mechanistic analyses identifies a significant, distinctive safety signal for interstitial lung disease associated with the combination of darolutamide and docetaxel, suggesting a synergistic interaction that warrants further clinical validation.

Original authors: Shenghao Wu, Keer Zhang, Qijing Sun, Ranran Zhou, Cundong Liu

Published 2026-07-23

📖 6 min read🧠 Deep dive

CC BY 4.0

Original authors: Shenghao Wu, Keer Zhang, Qijing Sun, Ranran Zhou, Cundong Liu

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

Imagine the human body as a bustling, high-tech city. In this city, the lungs are the air filtration towers, constantly working to keep the air clean and the citizens (cells) breathing easy. Sometimes, when the city faces a dangerous invasion—like cancer—the doctors send in a specialized cleanup crew called chemotherapy. One famous member of this crew is a drug called Docetaxel. It's a tough, effective worker that stops cancer cells from multiplying, but like any heavy machinery, it can sometimes accidentally damage the city's air filters, causing a condition known as Interstitial Lung Disease (ILD). Think of ILD as the filters getting clogged, scarred, or inflamed, making it hard for the city to breathe.

To fight cancer even better, doctors often pair this cleanup crew with a second type of worker called an Androgen Receptor Pathway Inhibitor (ARPI). These are like specialized detectives that hunt down the specific signals cancer cells use to grow. Recently, a new detective named Darolutamide has been teamed up with Docetaxel. It's a powerful new strategy, but the city planners (scientists) wanted to know: Does adding this new detective make the cleanup crew more likely to accidentally hurt the lungs? This is the big question behind the study we are about to explore. They didn't just guess; they looked at a massive digital logbook of real-world reports to see if this specific team-up was sending up more smoke signals than other similar teams.

The Great Drug Detective Hunt

In this study, a team of researchers acted like digital detectives. They didn't run a new experiment in a lab; instead, they went digging through the FAERS database. You can think of FAERS as a giant, global "complaint box" where doctors and patients report what happens when they take medicines. The researchers wanted to see if the combination of Darolutamide + Docetaxel was reporting more lung trouble than other similar combinations, like Enzalutamide + Docetaxel or Abiraterone + Docetaxel.

They started by sorting through thousands of reports. They found 555 reports for the Darolutamide team, 519 for the Enzalutamide team, and 421 for the Abiraterone team. When they looked at the "Respiratory, thoracic and mediastinal disorders" (a fancy way of saying "lung and chest problems"), the Darolutamide team stood out. They had 120 reports of these issues, which was significantly higher than the others.

But the real smoking gun was found when they zoomed in on Interstitial Lung Disease (ILD) specifically.

For the Darolutamide + Docetaxel team, there were 37 reports of ILD. The statistical "signal" for this was incredibly strong, with a number called a Reporting Odds Ratio (ROR) of 31.30.
In contrast, the Enzalutamide + Docetaxel team only had 4 reports of ILD (ROR of 3.40).
The Abiraterone + Docetaxel team also only had 4 reports (ROR of 3.88).

To put this in perspective, the researchers compared the Darolutamide team against the drugs used alone. When Darolutamide and Docetaxel were used together, the chance of reporting ILD was 22.66 times higher than when Darolutamide was used alone, and 13.31 times higher than when Docetaxel was used alone. This suggests that the two drugs together are doing something specific that neither does on its own.

The "Team-Up" Effect

The researchers wanted to be sure this wasn't just a coincidence. They used a special mathematical tool called Drug-Drug Interaction (DDI) analysis. Imagine you have two people, A and B. If A causes a problem 10% of the time, and B causes it 10% of the time, you might expect them to cause it 20% of the time if they work together. But sometimes, they might cause it 100% of the time because they accidentally push each other's buttons.

The study found that for the Darolutamide x Docetaxel pair, the "pushing buttons" effect was real. The statistical measure (called $\Omega$ ) was positive for ILD, meaning the combination was reporting lung issues more often than expected by just adding their individual risks. However, when they checked the other two teams (Enzalutamide and Abiraterone), they did not find this same "synergy." Those teams didn't show a special boost in lung trouble when paired with Docetaxel. This is a crucial distinction: the problem seems unique to the Darolutamide team-up, not just a general side effect of all prostate cancer treatments.

Who Gets Hit and When?

The detectives also looked at who was reporting these issues. They found that older patients (71 years and older) seemed to report respiratory problems slightly more often than younger patients, though the difference wasn't huge. The most interesting timing detail was how fast the trouble started. For the Darolutamide team, the first sign of trouble usually appeared around 27 days after starting the treatment. This is a relatively quick reaction, suggesting the lungs might be reacting to the new drug combination fairly soon after exposure.

The "Why" Behind the "What"

Since the database only tells them that something happened, not how or why, the researchers used a computer simulation method called Network Pharmacology. Think of this as building a digital map of how these drugs might interact with the body's genes.

They found that the combination of Darolutamide and Docetaxel seems to mess with several key biological pathways:

Xenobiotic response: How the body reacts to foreign chemicals.
Apoptosis: The process of cells deciding to die.
Gap junctions: The tiny channels cells use to talk to each other.
Calcium signaling and GPCR/cAMP pathways: Complex chemical messengers inside cells.

The simulation suggested that these drugs might be causing stress to the lung cells, triggering them to die or communicate incorrectly, which leads to inflammation and scarring. They identified key "hub genes" like MYC, TP53, KRAS, and PTEN that seem to be involved in this messy process. It's like the drugs are sending a confused message to the lung's repair crew, causing them to overreact and build a wall where there should be open air.

The Bottom Line

So, what did this study actually prove? It didn't prove that every patient will get lung disease, nor did it calculate the exact percentage of people who will get sick. The FAERS database is a collection of reports, not a census, so we don't know the total number of people taking the drugs to calculate a true risk rate.

However, the study strongly suggests that the combination of Darolutamide and Docetaxel carries a distinctive signal for Interstitial Lung Disease that is not seen with other similar drug combinations. The statistical signals are loud and clear: the reporting odds are high, the interaction models support it, and the computer simulations offer a plausible biological story for why it might happen.

The authors conclude that this is a "pharmacovigilance cue." In plain English, this means: "We've spotted a red flag. We aren't 100% sure of the cause-and-effect yet, but the evidence is strong enough that doctors should keep a very close eye on patients taking this specific combination, especially if they start coughing or getting short of breath." It's a call for more careful monitoring and further study to confirm exactly how often this happens and how to prevent it.

Technical Summary: Risks Associated with the Combination of Darolutamide and Docetaxel in Interstitial Lung Disease

Problem Statement
Metastatic hormone-sensitive prostate cancer (mHSPC) treatment has evolved toward intensification regimens combining androgen receptor pathway inhibitors (ARPIs) with docetaxel. While regimens such as darolutamide + docetaxel, enzalutamide + docetaxel, and abiraterone + docetaxel are established first-line options, their specific pulmonary safety profiles remain incompletely characterized. Although docetaxel is known to cause interstitial lung disease (ILD), it is unclear whether the addition of specific ARPIs, particularly darolutamide, creates a distinctive synergistic pulmonary toxicity signal that exceeds the background risk of docetaxel alone or other ARPI combinations. This study addresses the need to detect and characterize potential low-frequency but severe ILD signals associated with the darolutamide + docetaxel combination using real-world data.

Methodology
The study employed a multi-faceted pharmacovigilance approach using the FDA Adverse Event Reporting System (FAERS) database, supplemented by network pharmacology and computational modeling.

Data Source and Screening: The analysis utilized FAERS case safety reports from 2004 to 2025. Reports were filtered for prostate cancer indications, excluding benign tumors and non-study indications. Three combination groups were defined: darolutamide + docetaxel (2021Q3–2025Q4), enzalutamide + docetaxel (2012Q3–2025Q4), and abiraterone + docetaxel (2011Q2–2025Q4). Reports required the coexistence of both drugs in the same primary ID, with at least one designated as a primary suspect.
Disproportionality Analysis: Signals were detected using four algorithms: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Information Component (IC), and Empirical Bayesian Geometric Mean (EBGM). Analyses were conducted at the System Organ Class (SOC) and Preferred Term (PT) levels.
Comparative and Interaction Analyses:
- Comparative ROR: Directly compared the reporting tendency of adverse events between the darolutamide + docetaxel group and the other ARPI + docetaxel groups, as well as against monotherapy backgrounds.
- Drug-Drug Interaction (DDI): Evaluated whether the reporting of ILD in the combination group exceeded the expected additive or multiplicative risk of the individual drugs using the $\Omega$ shrinkage measure, supported by additive, multiplicative, and Combination Risk Ratio (CRR) models.
Subgroup and Temporal Analysis: Age subgroups (elderly vs. young) and Time-to-Onset (TTO) were analyzed to characterize the demographic and temporal profile of the adverse events.
Mechanistic Exploration: Network pharmacology integrated target genes of darolutamide and docetaxel with ILD-related genes from multiple databases (GeneCards, DisGeNET, etc.). Protein-Protein Interaction (PPI) networks identified hub genes. Pathway enrichment (GO, KEGG, Reactome) and molecular docking (AutoDock Vina) were performed to explore potential biological mechanisms and binding affinities.

Key Results

Signal Detection: Among 555 reports for darolutamide + docetaxel, respiratory, thoracic, and mediastinal disorders were significantly prominent (N=120; ROR=2.62). Specifically, ILD was the most distinctive signal (N=37; ROR=31.30, 95% CI 22.42–43.70), accompanied by pneumonitis and dyspnea.
Comparative Specificity: The ILD signal for darolutamide + docetaxel was significantly stronger than for enzalutamide + docetaxel (Comparative ROR = 0.11) and abiraterone + docetaxel (Comparative ROR = 0.17).
Monotherapy Comparison: The combination group showed a significantly higher reporting tendency for ILD compared to darolutamide monotherapy (Comparative ROR = 22.66) and docetaxel monotherapy (Comparative ROR = 13.31).
DDI Validation: The darolutamide $\times$ docetaxel pair met the positive criteria ( $\Omega_{0.25} > 0$ ) for ILD, Core_ILD, and Broad_ILD_like PTs across additive, multiplicative, and CRR models. In contrast, enzalutamide $\times$ docetaxel and abiraterone $\times$ docetaxel did not show positive interaction signals for ILD.
Demographics and Timing: Respiratory disorders, including pulmonary inflammation and respiratory failure, were more frequent in the elderly subgroup (≥71 years). The median time to onset for respiratory disorders was 41 days for the darolutamide + docetaxel group.
Mechanistic Insights: Network pharmacology identified 119 intersection genes, with hub genes including MYC, TP53, KRAS, ATM, PIK3CA, PTEN, CCND1, and BRCA1. Pathway enrichment highlighted xenobiotic response, apoptosis, gap junction, calcium signaling, and GPCR/cAMP signaling. Molecular docking confirmed potential binding between the drugs and these hub proteins (binding energy < -4 kcal/mol).

Key Contributions
This study provides the first pharmacovigilance evidence suggesting a distinctive ILD signal specific to the darolutamide + docetaxel combination, which persists across multiple statistical models (disproportionality, comparative ROR, and DDI) and is not observed with other ARPI + docetaxel regimens. By integrating real-world data with network pharmacology, the study proposes a mechanistic hypothesis involving drug stress, epithelial/endothelial injury, and altered intercellular communication (gap junctions) mediated by specific hub genes.

Significance and Claims
The authors assert that while the study does not establish clinical incidence or causality due to the inherent limitations of spontaneous reporting databases (lack of denominators, reporting bias), the findings support darolutamide + docetaxel-related ILD as a critical pharmacovigilance cue. The distinctive nature of the signal, validated by DDI analysis and supported by mechanistic modeling, warrants priority validation through clinical cohorts and closer surveillance. The study concludes that this combination may require specific clinical monitoring for ILD, distinguishing it from the general docetaxel toxicity profile shared by other ARPI combinations.